EUVIMEDOpdag EUVIMED
MetaanalyseÜbersichtsarbeitOpen access · CC BY-NC-ND 4.0

Meta‐analysis: Risk of pancreatic cancer in patients with inflammatory bowel disease

Mohammad Zamani iD, Shaghayegh Alizadeh-Tabari, Mohammad Hassan Murad, Ashwin N Ananthakrishnan iD, Reza Malekzadeh iD, Nicholas J Talley iD

Alimentary Pharmacology & Therapeutics · 2024-04 · 59 (8) · 918-927

DOI: 10.1111/apt.17919 ↗

At a glance

Metaanalyse in Alimentary Pharmacology & Therapeutics, published online on 2024-02-19. Written by Mohammad Zamani and 5 co-authors. Institution: Digestive Diseases Research Center, Digestive Diseases Research Institute, Tehran University of Medical Sciences, Tehran, Iran. Major MEDLINE topics: Colitis, Ulcerative, Crohn Disease, Inflammatory Bowel Diseases, Pancreatic Neoplasms. Cited 18 times so far (Crossref); 44 references. The full text is freely available (open access, CC BY-NC-ND 4.0).

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Background

Studies exploring the association between inflammatory bowel disease (IBD) and pancreatic cancer have reported inconsistent results.

Aims

To provide a comprehensive overview of the risk of pancreatic cancer development in patients with IBD.

Methods

We searched Embase, PubMed, Scopus and ProQuest from inception to 31 October 2023. We included population‐based cohort studies examining the risk of incident pancreatic cancer in adult patients with IBD compared to the non‐IBD population. We also retrieved Mendelian randomisation (MR) studies investigating the relationship of IBD with pancreatic cancer risk. We conducted random‐effects meta‐analyses and provided pooled relative risks (RRs) with 95% confidence intervals (CIs).

Results

We included 13 studies. Among 11 cohort studies, the risk of developing pancreatic cancer increased by 79% in patients with IBD (RR = 1.79 [95% CI: 1.16–2.75]; I 2 = 95.7%). Patients either with Crohn's disease (RR = 1.42 [95% CI: 1.24–1.63]) or ulcerative colitis (RR = 1.50 [95% CI: 1.17–1.92]) had increased risk ( p for interaction = 0.72). The annual incidence of pancreatic cancer potentially attributable to IBD increased by 55 cases (95% CI: 17–103) per million. Two MR studies demonstrated that genetic liability to IBD was associated with an increased risk of pancreatic cancer.

Conclusions

Our results suggest a moderate increase in the risk of pancreatic cancer in patients with IBD, which may be further heightened by genetic predisposition to IBD. The increased risk of pancreatic cancer is probably similar in Crohn's disease and ulcerative colitis.

Subjects

MeSH terms (MEDLINE)

Colitis, UlcerativeCrohn DiseaseInflammatory Bowel DiseasesPancreatic NeoplasmsAdultHumansRisk

Authors and institutions

  • Digestive Diseases Research Center, Digestive Diseases Research Institute, Tehran University of Medical Sciences, Tehran, Iran.
  • Kern Center for the Science of Healthcare Delivery Research, Mayo Clinic, Rochester, Minnesota, USA.
  • Division of Gastroenterology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.
  • Digestive Oncology Research Center, Digestive Diseases Research Institute, Tehran University of Medical Sciences, Tehran, Iran.
  • School of Medicine and Public Health, University of Newcastle, Newcastle, New South Wales, Australia.

ORCID profiles: Mohammad Zamani, Ashwin N Ananthakrishnan, Reza Malekzadeh, Nicholas J Talley

Cite

APA

Zamani, M., Alizadeh-Tabari, S., Murad, M. H., Ananthakrishnan, A. N., Malekzadeh, R., & Talley, N. J. (2024). Meta‐analysis: Risk of pancreatic cancer in patients with inflammatory bowel disease. Alimentary Pharmacology & Therapeutics, 59(8), 918-927. https://doi.org/10.1111/apt.17919

Vancouver

Zamani M, Alizadeh-Tabari S, Murad MH, Ananthakrishnan AN, Malekzadeh R, Talley NJ. Meta‐analysis: Risk of pancreatic cancer in patients with inflammatory bowel disease. Alimentary Pharmacology & Therapeutics. 2024;59(8):918-927. doi:10.1111/apt.17919

BibTeX
@article{Zamani2024,
  author = {Zamani, Mohammad and Alizadeh-Tabari, Shaghayegh and Murad, Mohammad Hassan and Ananthakrishnan, Ashwin N and Malekzadeh, Reza and Talley, Nicholas J},
  title = {Meta‐analysis: Risk of pancreatic cancer in patients with inflammatory bowel disease},
  journal = {Alimentary Pharmacology & Therapeutics},
  year = {2024},
  volume = {59},
  number = {8},
  pages = {918--927},
  doi = {10.1111/apt.17919}
}
Start for free →